Head-To-Head Review: Oncobiologics (OTLK) versus Its Competitors

Oncobiologics (NASDAQ:OTLK) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Oncobiologics to similar companies based on the strength of its risk, earnings, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Valuation & Earnings

This table compares Oncobiologics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oncobiologics	-$1.16 million	-$62.42 million	-0.62
Oncobiologics Competitors	$752.85 million	$13.49 million	-19.24

Oncobiologics’ rivals have higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Oncobiologics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Oncobiologics Competitors	-12,323.33%	-195.38%	-30.39%

Volatility and Risk

Oncobiologics has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Oncobiologics’ rivals have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Oncobiologics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1	2	2	0	2.20
Oncobiologics Competitors	9869	15281	45598	1598	2.54

Oncobiologics currently has a consensus price target of $5.20, suggesting a potential upside of 981.08%. As a group, “Biotechnology” companies have a potential upside of 120.47%. Given Oncobiologics’ higher possible upside, research analysts plainly believe Oncobiologics is more favorable than its rivals.

Institutional & Insider Ownership

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Oncobiologics rivals beat Oncobiologics on 8 of the 13 factors compared.

About Oncobiologics

Oncobiologics, now known as Outlook Therapeutics, Inc. (NASDAQ: OTLK), is a biopharmaceutical company focused on developing and commercializing ophthalmic therapies for retinal diseases. The company was established as Oncobiologics and later changed its name to Outlook Therapeutics to reflect its emphasis on eye-care products. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab designed for intravitreal use. The therapy has been studied for vascular retinal conditions, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion.